CMA_Article - TITLE: ECONOMIC ANALYSIS OF ONCOPLATIN ALONE...

Info iconThis preview shows pages 1–2. Sign up to view the full content.

View Full Document Right Arrow Icon
TITLE: ECONOMIC ANALYSIS OF ONCOPLATIN ALONE (A CHEMOTHERAPY AGENT) COMPARED WITH ONCOPLATIN COMBINED WITH NONAUSEA (AN ANTINAUSEA AGENT) BACKGROUND: A relatively new chemotherapy agent, Oncoplatin, is administered intravenously in physician offices and clinics. Originally, because of problems with chemotherapy-induced nausea, the recommended administration directions were to split the monthly dose needed for each cycle in half and administer each half 5 days apart. Followup studies found that if patients were given NoNausea, an antinausea medication, at the same visit, the full monthly dose of Oncoplatin could be given at one visit. Clinical effectiveness measures of the chemotherapy treatment were shown to be the same for the two methods of administration. OBJECTIVE: The objective of the study was to perform a cost-minimization analysis (CMA) comparing the cost of Oncoplatin given in two doses with Oncoplatin combined with NoNausea administered in one dose. The perspective of the study is the third-party payer. METHODS:
Background image of page 1

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
Image of page 2
This is the end of the preview. Sign up to access the rest of the document.

This note was uploaded on 04/30/2011 for the course ECON 2201 taught by Professor Nair during the Spring '11 term at St. John's.

Page1 / 2

CMA_Article - TITLE: ECONOMIC ANALYSIS OF ONCOPLATIN ALONE...

This preview shows document pages 1 - 2. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online